Nippon Shinyaku Co., Ltd. (4516)

Name: Nippon Shinyaku Co., Ltd. (4516) — histórico de demonstrações financeiras
Creator: TickerBase
License: https://creativecommons.org/licenses/by/4.0/

Histórico de receita, lucros e fluxo de caixa das demonstrações financeiras oficiais.

Healthcare · Wall Street (EUA) · Última atualização: 2026-10-02

Nippon Shinyaku Co., Ltd. manufactures and sells pharmaceuticals and foodstuffs in Japan, Europe, Switzerland, the United States, and internationally. The company operates through Pharmaceuticals and Functional Food Business segments. It offers drugs in the fields of urology, hematology, intractable and rare diseases, gynecology, and other diseases; health food ingredients, preservatives, protein preparations, and supplements. The company in the Strategic Partnership with Atthena Therapeutics, Inc.

Números-chave

Capitalização de mercado: JPY 228 billion
Receita (exercício encerrado em 2026-03-31): JPY 170.8B
Lucro líquido: JPY 29.7B
Margem bruta: 66.4%
Margem líquida: 17.4%

Ver gráficos interativos e demonstrações completas → Modelo de avaliação (DCF) →

Demonstração de resultados anual

Demonstração de resultados	2026-03-31	2025-03-31	2024-03-31	2023-03-31
Receita total	JPY 170.8B	JPY 160.2B	JPY 148.3B	JPY 144.2B
Lucro bruto	JPY 113.3B	JPY 109.1B	JPY 98.0B	JPY 88.2B
Resultado Operacional (EBIT)	JPY 35.5B	JPY 35.5B	JPY 33.3B	JPY 30.1B
Resultado líquido	JPY 29.7B	JPY 32.6B	JPY 25.9B	JPY 22.8B

Fonte: relatórios públicos da empresa (SEC). Verifique no SEC EDGAR antes de confiar em qualquer número.

Balanços, fluxos de caixa, dados trimestrais e indicadores completos no visualizador interativo de 4516. /companies/us/4516

Empresas semelhantes

As informações deste site são apenas educacionais e informativas; não constituem recomendação de investimento. Não publicamos preços-alvo nem recomendações.

English version →Todas as ações

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.